Literature DB >> 11533891

[Buprenorphine in pregnancy].

H Eder1, I Rupp, A Peternell, G Fischer.   

Abstract

The treatment of opioid dependence during pregnancy is a major challenge for doctors, social workers and gynaecologists. Continuous drug abuse during pregnancy can lead to a variety of complications in the mother, fetus and neonate. lt is recommended practice to maintain pregnant opioid-dependent women with synthetic opioids and according to international guidelines, methadone is the recommended substance so far. However, a neonatal abstinence syndrome (NAS) of varying severity is observed in 60 - 80 % of the neonates with even a longer course of duration in comparison to the NAS after heroin consumption during pregnancy. NAS is characterised by tremor, irritability, hypertonicity, vomiting, sneezing, fever, poor suckling, and sometimes convulsions. Recent studies have investigated the safety and efficacy of other synthetic opioids like sublingual buprenorphine for the treatment of pregnant patients. We present a 22 year old opioid-dependent woman, who has been maintained continuously on buprenorphine for 3 years. During the treatment episode she delivered two healthy newborns and both did not show any symptoms of NAS. The maintenance therapy with buprenorphine proved safety and efficacy during pregnancy, the mother was free of continuous heroin abuse, verified through supervised urine-toxicology. The quantitative and qualitative difference in NAS may be explained by the partial mu-receptor agonist and kappa-antagonist receptor profile of buprenorphine compared to pure mu-agonist action of methadone or heroin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533891     DOI: 10.1055/s-2001-16875

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  5 in total

1.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

2.  [Transdermal buprenorphine during pregnancy].

Authors:  E Ebner; M Wiedmann
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

3.  Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.

Authors:  Isabelle Lacroix; Alain Berrebi; Daniel Garipuy; Laurent Schmitt; Yamina Hammou; Catherine Chaumerliac; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Christine Damase-Michel
Journal:  Eur J Clin Pharmacol       Date:  2011-05-03       Impact factor: 2.953

Review 4.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.